347 related articles for article (PubMed ID: 28851046)
1. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
[TBL] [Abstract][Full Text] [Related]
2. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
4. Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis.
Miyamoto E; Chen-Yoshikawa TF; Ueshima C; Yoshizawa A; Hamaji M; Yamamoto T; Kawada K; Haga H; Sakai Y; Date H
J Surg Oncol; 2018 Jun; 117(7):1405-1412. PubMed ID: 29663398
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
Kim JH; Park HE; Cho NY; Lee HS; Kang GH
Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
9. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
10. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
12. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
Front Immunol; 2021; 12():679090. PubMed ID: 34054869
[TBL] [Abstract][Full Text] [Related]
14. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.
Song M; Chen D; Lu B; Wang C; Zhang J; Huang L; Wang X; Timmons CL; Hu J; Liu B; Wu X; Wang L; Wang J; Liu H
PLoS One; 2013; 8(6):e65821. PubMed ID: 23785454
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
[TBL] [Abstract][Full Text] [Related]
16. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice.
Zhang M; Jiang H; Zhang R; Jiang H; Xu H; Pan W; Gao X; Sun Z
J Cell Biochem; 2019 Jun; 120(6):10239-10247. PubMed ID: 30609118
[TBL] [Abstract][Full Text] [Related]
17. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Zhao L; Yu H; Yi S; Peng X; Su P; Xiao Z; Liu R; Tang A; Li X; Liu F; Shen S
Oncotarget; 2016 Jul; 7(29):45370-45384. PubMed ID: 27248318
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
[TBL] [Abstract][Full Text] [Related]
20. The role of the immunoescape in colorectal cancer liver metastasis.
Takasu C; Yamashita S; Morine Y; Yoshikawa K; Tokunaga T; Nishi M; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2021; 16(11):e0259940. PubMed ID: 34797860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
